BACKGROUND: The ART score (a point score for the assessment of retreatment with transarterial chemoembolization, TACE) has been recently developed in Austria to differentiate patients who may benefit from multiple sessions of TACE for hepatocellular carcinoma (HCC) treatment. The primary aim of the study was to test the validity of the ART score in an Italian study cohort. The secondary aims were to evaluate overall survival (OS) and clinical determinants of improved survival in patients treated with multiple TACE sessions. METHODS: The ART score and the clinical outcome of 51 consecutive patients with HCC submitted to multiple TACE sessions from April 2002 to December 2009 were retrospectively analyzed. RESULTS: Median OS was 26.0 months (95% confidence interval 18.4-33.6) with 1-, 3- and 5-year survival rates of 75, 33 and 11%, respectively). Thirty-three patients had an ART score of 0-1.5 and in 18 it was ≥2.5, but in our patient series, the ART score was not found to be a predictor of survival (p = 0.173). At univariate analysis, tumor extent (uni- vs. bilobar: 34.0 vs. 9.0 months; p < 0.001), Child-Pugh score before the second TACE (A vs. B7 vs. B8-9: 26.0 vs. 16.0 vs. 5.0 months; p = 0.005) and Child-Pugh score increase between the first and second TACE (absent vs. + 1 point vs. + ≥2 points: 27.0 vs. 4.0 vs. 5.0 months; p < 0.001) were statistically related with survival. At multivariate analysis, only Child-Pugh score increase remained a significant predictor of worse survival (p = 0.001, hazard rate = 11.6). CONCLUSIONS: The ART score was not found to work as an objective tool to guide TACE retreatment in our Italian patient series, only the Child-Pugh score increase was an independent predictor of a shorter survival.
BACKGROUND: The ART score (a point score for the assessment of retreatment with transarterial chemoembolization, TACE) has been recently developed in Austria to differentiate patients who may benefit from multiple sessions of TACE for hepatocellular carcinoma (HCC) treatment. The primary aim of the study was to test the validity of the ART score in an Italian study cohort. The secondary aims were to evaluate overall survival (OS) and clinical determinants of improved survival in patients treated with multiple TACE sessions. METHODS: The ART score and the clinical outcome of 51 consecutive patients with HCC submitted to multiple TACE sessions from April 2002 to December 2009 were retrospectively analyzed. RESULTS: Median OS was 26.0 months (95% confidence interval 18.4-33.6) with 1-, 3- and 5-year survival rates of 75, 33 and 11%, respectively). Thirty-three patients had an ART score of 0-1.5 and in 18 it was ≥2.5, but in our patient series, the ART score was not found to be a predictor of survival (p = 0.173). At univariate analysis, tumor extent (uni- vs. bilobar: 34.0 vs. 9.0 months; p < 0.001), Child-Pugh score before the second TACE (A vs. B7 vs. B8-9: 26.0 vs. 16.0 vs. 5.0 months; p = 0.005) and Child-Pugh score increase between the first and second TACE (absent vs. + 1 point vs. + ≥2 points: 27.0 vs. 4.0 vs. 5.0 months; p < 0.001) were statistically related with survival. At multivariate analysis, only Child-Pugh score increase remained a significant predictor of worse survival (p = 0.001, hazard rate = 11.6). CONCLUSIONS: The ART score was not found to work as an objective tool to guide TACE retreatment in our Italian patient series, only the Child-Pugh score increase was an independent predictor of a shorter survival.
Authors: Matteo Renzulli; Nicolò Brandi; Anna Pecorelli; Luigi Vincenzo Pastore; Alessandro Granito; Giuseppe Martinese; Francesco Tovoli; Mario Simonetti; Elton Dajti; Antonio Colecchia; Rita Golfieri Journal: Diagnostics (Basel) Date: 2022-03-29
Authors: David J Pinato; Tadaaki Arizumi; Jeong Won Jang; Elias Allara; Puvan I Suppiah; Carlo Smirne; Paul Tait; Madhava Pai; Glenda Grossi; Young Woon Kim; Mario Pirisi; Masatoshi Kudo; Rohini Sharma Journal: Oncotarget Date: 2016-07-12
Authors: Aline Mähringer-Kunz; Arndt Weinmann; Irene Schmidtmann; Sandra Koch; Sebastian Schotten; Daniel Pinto Dos Santos; Michael Bernhard Pitton; Christoph Dueber; Peter Robert Galle; Roman Kloeckner Journal: BMC Cancer Date: 2018-04-27 Impact factor: 4.430
Authors: Jae Seung Lee; Beom Kyung Kim; Seung Up Kim; Jun Yong Park; Sang Hoon Ahn; Jin Sil Seong; Kwang-Hyub Han; Do Young Kim Journal: Clin Mol Hepatol Date: 2019-05-20
Authors: Joon Yeul Nam; A Reum Choe; Dong Hyun Sinn; Jeong-Hoon Lee; Hwi Young Kim; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon; Jeong Min Lee; Jin Wook Chung; Sun Young Choi; Jeong Kyong Lee; Seung Yon Baek; Hye Ah Lee; Tae Hun Kim; Kwon Yoo Journal: BMC Cancer Date: 2020-06-01 Impact factor: 4.430